Cargando…

Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials

BACKGROUND: Immunosuppressive agents have been widely used in the treatment of IgA nephropathy (IgAN), but the efficacy and safety remain controversial. The recent STOP-IgAN and TESTING studies have again focused attention on the application of immunosuppressive agents in IgAN. This study investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zheng, Yang, Yue, Jiang, Shi-min, Li, Wen-ge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710882/ https://www.ncbi.nlm.nih.gov/pubmed/31455248 http://dx.doi.org/10.1186/s12882-019-1519-3

Ejemplares similares

Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis
por: Han, Shisheng, et al.
Publicado: (2021)

The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis
por: Tan, Jiaxing, et al.
Publicado: (2020)

Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials
por: Zheng, Jian-Nan, et al.
Publicado: (2018)

Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis
por: Liu, Tongtong, et al.
Publicado: (2021)

Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis
por: Song, Yu-Huan, et al.
Publicado: (2017)

Efficacy and safety of sequential immunosuppressive treatment for severe IgA nephropathy: A retrospective study
por: Luo, Mian-Na, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials
por: Yang, Pingping, et al.
Publicado: (2018)

Efficacy and safety of Telitacicept in patients with IgA nephropathy
por: Liang, Dongrui, et al.
Publicado: (2023)

Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment
por: Feng, Qipu, et al.
Publicado: (2022)

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
por: Du, Bing, et al.
Publicado: (2017)

Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
por: Kim, Min Jeong, et al.
Publicado: (2016)

Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History
por: Wu, Haiting, et al.
Publicado: (2020)

Efficacy and safety of leflunomide combined with corticosteroids for the treatment of IgA nephropathy: a Meta-analysis of randomized controlled trials
por: Lv, Guangxin, et al.
Publicado: (2022)

Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: A meta-analysis
por: Liu, Yanli, et al.
Publicado: (2016)

Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: A meta-analysis
por: Liu, Yanli, et al.
Publicado: (2019)

Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis
por: Zhang, Yong, et al.
Publicado: (2018)

Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials
por: ZHAO, Yu, et al.
Publicado: (2019)

Homocysteine and IgA nephropathy: observational and Mendelian randomization analyses
por: Zhang, Yue-Miao, et al.
Publicado: (2020)

Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review
por: Chen, Youyuan, et al.
Publicado: (2014)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy
por: Le, Wei-Bo, et al.
Publicado: (2022)

Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy
por: Kim, Yong-Chul, et al.
Publicado: (2013)

Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features
por: Cambier, Alexandra, et al.
Publicado: (2018)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria
por: Lv, Jicheng, et al.
Publicado: (2022)

Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy
por: Chen, Tingyu, et al.
Publicado: (2020)

Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?
por: Obrișcă, Bogdan, et al.
Publicado: (2019)

Safety Evaluation of COVID-19 Vaccine in Patients With IgA Nephropathy or IgA Vasculitis Nephritis
por: Zan, Jincan, et al.
Publicado: (2022)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy
por: Papasotiriou, Marios, et al.
Publicado: (2022)

Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
por: Zhao, Lijuan, et al.
Publicado: (2023)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
por: Nihei, Yoshihito, et al.
Publicado: (2023)

The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study
por: Liang, Mengjun, et al.
Publicado: (2022)

Tripterygium Wilfordii inhibits tonsillar IgA production by downregulating IgA class switching in IgA nephropathy
por: Li, Huining, et al.
Publicado: (2017)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports
por: Tota, Maciej, et al.
Publicado: (2023)

Role of immunosuppressive therapy and predictors of therapeutic effectiveness and renal outcome in IgA nephropathy with proteinuria
por: Ruan, Yiping, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cmh2d35054n32jgl11m84tkb1k